Biogen Idec Inc. shares (NASDAQ:BIIB) rose a healthy 6.4 percent, or $19.83, to $328.27 Tuesday as investors swooned over news the company is aggressively advancing plans for a phase III study of its experimental Alzheimer's disease (AD) drug, BIIB037, also known as aducanumab.